Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

DOI: 10.1038/s41591-025-03566-1Author: Ramez N. Eskander et al.Published: 2025-5

Title: Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
Journal: Nature Medicine
Authors: Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda B. Musa, Robert S. Mannel, Mark S. Shahin, Guilherme H. Cantuaria, Eugenia Girda, Elizabeth Lokich, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily M. Hinchcliff, Shashikant B. Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
Date: 2025-5
DOI: 10.1038/s41591-025-03566-1
Source: Springer Science and Business Media LLC
Source URL: https://doi.org/10.1038/s41591-025-03566-1